

**DEVELOPMENT OF NOVEL THERAPEUTICS
TARGETING TRANSIENT RECEPTOR POTENTIAL
CHANNEL MEDIATED NOCICEPTION FOR THE
TREATMENT OF CHEMOTHERAPY-INDUCED
NEUROPATHIC PAIN**



**Thesis submitted in partial fulfilment for the
Award of Degree**

DOCTOR OF PHILOSOPHY

By

AKHILESH

**DEPARTMENT OF PHARMACEUTICAL ENGINEERING & TECHNOLOGY
INDIAN INSTITUTE OF TECHNOLOGY
(BANARAS HINDU UNIVERSITY)
VARANASI - 221005
INDIA**

Roll No: 20161510

Year : 2024

Dedicated to

“To the future generations of scientists who will continue to build upon our work, pushing the boundaries of what is known and striving for new breakthroughs in pain management”



CERTIFICATE

It is certified that the work contained in the thesis titled "*Development of Novel Therapeutics Targeting Transient Receptor Potential Channel Mediated Nociception for the Treatment of Chemotherapy-Induced Neuropathic Pain*" by **AKHILESH** has been carried out under my supervision and that this work has been not submitted elsewhere for a degree.

It is further certified that the student has fulfilled all the requirements of Course work, Comprehensive, Candidacy, SOTA and Pre-submission seminar.

Vinod
13/02/2024

डा० विनोद तिवारी / Dr. Vinod Tiwari

सह-आचार्य / Associate Professor

धैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग /
Department of Pharmaceutical Engineering & Technology

भारतीय प्रौद्योगिकी संस्थान / Indian Institute of Technology

(काशी हिन्दू विश्वविद्यालय) / (Banaras Hindu University)

वाराणसी-२२१००५ / Varanasi-221005

Dr. Vinod Tiwari

Department of Pharmaceutical Engineering & Technology

Indian Institute of Technology (BHU), Varanasi

DECLARATION BY THE CANDIDATE

I, **Akhilesh**, certify that the work embodied in this Ph.D. thesis is my own bonafide work and carried out by me under the supervision of **Dr. Vinod Tiwari** from **January, 2021 to February, 2024** at the **Department of Pharmaceutical Engineering & Technology**, Indian Institute of Technology (B.H.U.), Varanasi. The matter embodied in this thesis has not been submitted for the award of any other degree/diploma.

I declare that I have faithfully acknowledged and given credits to the research workers wherever their works have been cited in my work in this thesis. I further declare that I have not willfully copied any other's work, paragraphs, text, data, results, etc., reported in journals, books, magazines, reports, dissertations, thesis, etc., or available at websites and have not included them in this Ph.D. thesis and have not cited as my own work.

Date: **13/02/2024**

Place: **Varanasi**


(Akhilesh)

CERTIFICATE FROM THE SUPERVISOR

It is certified that the above statement made by the student is correct to the best of my/our knowledge.



(Dr. Vinod Tiwari)

Supervisor

डा० विनोद तिवारी / Dr. Vinod Tiwari
सह-आचार्य / Associate Professor
भैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग /
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / Indian Institute of Technology
(काशी हिन्दू विश्वविद्यालय) / (Banaras Hindu University)
वाराणसी-२२१००५ / Varanasi-221005


(Prof. S. Hemalatha)

Head of the Department

विभागाध्यक्ष / Head

भैषजकीय अभियांत्रिकी एवं प्रौद्योगिकी विभाग /
Department of Pharmaceutical Engineering & Technology
भारतीय प्रौद्योगिकी संस्थान / INDIAN INSTITUTE OF TECHNOLOGY
(बनारस हिन्दू विश्वविद्यालय) / (BANARAS HINDU UNIVERSITY)
वाराणसी-२२१००५ / Varanasi-221005

COPYRIGHT TRANSFER CERTIFICATE

Title of the Thesis : “Development of Novel Therapeutics Targeting Transient Receptor Potential Channel Mediated Nociception for the Treatment of Chemotherapy-Induced Neuropathic Pain”

Name of the Student : Mr. Akhilesh

Copyright Transfer

The undersigned hereby assigns to the Indian Institute of Technology (B.H.U.), Varanasi all rights under copyright that may exist in and for the above thesis submitted for the award of the “**Doctor of Philosophy**”

Date: 13/02/2024

Place: Varanasi


(Akhilesh)

Note: However, the author may reproduce or authorize others to reproduce material extracted verbatim from the thesis or derivative of the thesis for author's personal use provided that the source and the Institute's copyright notice are indicated.

ACKNOWLEDGEMENTS

My first and foremost heartfelt gratitude and indebtedness would be towards Bharat Ratna Mahamana Pandit Madan Mohan Malviya Ji, the founder of Banaras Hindu University, who sacrificed his entire life and efforts in establishing this artistic temple of knowledge and wisdom.

I would like to express my sincere gratitude to my esteemed supervisor Dr. Vinod Tiwari for his unwavering support, boundless patience, and invaluable guidance throughout my Ph.D. research journey. I have truly benefited from his extensive knowledge, vast research experience, and insightful suggestions that have significantly enriched my work. I am sincerely thankful that he took me under his wing as his student and maintained faith in my abilities over the years. I am at a loss for words to convey the depth of my appreciation for his role in shaping me not only into a proficient researcher but also into a better individual. His mentorship has been instrumental in my personal and academic growth. I owe him a debt of gratitude for the person I am today and for the promising future that lies ahead.

I owe my sincere thanks to Prof. Siva Hemalatha, Head, Department of Pharmaceutical Engineering & Technology, I.I.T. (B.H.U.), Varanasi for providing the necessary facilities during the course of the work. I would also like to express my sincere thanks to RPEC member's Dr. Shreynash Kumar Jain, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University) and Dr. Vishal Mishra, School of Biochemical Engineering, Indian Institute of Technology (Banaras Hindu University) for their valuable inputs and criticism which incited me to widen my research from various perspectives.

I would like to thank all the faculty members of the department Prof. B. Mishra, Prof. Sanjay Singh, Prof. S. K. Singh, Prof. S. K. Shrivastava, Prof. K. Sairam, Prof. A. Senthil Raja, Prof. M.S. Muthu, Dr. A. N Sahu, Dr. Ruchi Chawla, Dr. Gyan Prakash Modi, Dr. S. K. Jain, Dr. Ashish Agarwal, Dr. S. K. Mishra, Dr. Prasanta Kumar Nayak, Dr. Rajnish, Dr. Deepak, Dr. Dinesh, Dr. Jai Ram Meena and Dr. Arun Khatri for their kind support during the progress of my research. I greatly acknowledge the Central Instrumentation Lab, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U), and Interdisciplinary School of Life Sciences (ISLS), B.H.U. Varanasi, for providing the instrumental facility for the research work.

I express my sincere appreciation to our collaborators Prof. S. K. Shrivastava, Dr. Rajinsh Kumar and Dr. Digambar Kumar Waiker from the Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (B.H.U), Varanasi for their invaluable assistance with computational work throughout the completion of this PhD thesis.

During the course of my PhD, I had the chance to interact with Prof. Srinivasa N. Raja, Director of Pain Research at The Johns Hopkins University School of Medicine, Baltimore, MD, USA. I sincerely thank Prof. Raja for his valuable insights and suggestions which played a significant role in giving direction to my research. I am very thankful to Prof. S.P. Singh, Professor in the Department of Biochemistry, (B.H.U), Varanasi for providing the research support and facilities that I needed to successfully complete my studies.

The efforts of the non-teaching staff Mr. Vipin Pandey, Mr. Yashwant Singh, Mr. Atul, Mr. Anand, Mr. Siddhant, Mr. A.N. Upadhyay, Mr. Arun, Mr. Virendra, Mr. Jameel, and other non-teaching staff members of the department could never go unnoticed who continuously lent their support and technical assistance during the tenure of the research.

I am indeed thankful to my colleagues and juniors Dr. Anurag Kumar Singh, Dr. Ankit Uniyal, Ms. Anagha Gadepalli, Mr. Deepak Chouhan, Mr. Obulapathi Ummadisetty, Mr. Somesh Agrawal, Ms. Alani Meghana, Ms. Priyanka Pandey who provided stimulating discussions as well as happy distractions to rest my mind outside of my research. I would like to thank all my M. Pharm. and B. Tech IDD juniors Mr. Tapas, Ms. Sneha, Mr. Narendra, Mr. Nagendra, Mr. Lavan, Mr. Akash, Mr. Ajay, Ms. Mousmi Rani, Ms. Shreya Khanna and Ms. Shreya Solanki, Ms. Anmol, Ms. Nivedita Verma, Mr. Krushna, Mr Anuj for their pleasant company, co-operation, and maintaining a positive environment in the lab. I would be amiss if I did not mention Dr. Ajay Shanakar Bangwal, Dr. Hareram Birla, Dr. Soumitra Singh Sen, Dr. Aaina Singh Rathore, Dr. Hagera Dilnashin, for their support and cooperation. The moral support and constant motivation which I have always received from my friends cannot be expressed in words and I feel blessed with such wonderful friends. Some of them who deserve special thanks are Dr. Ajay, Dr. Manisha, Mr. Nihar. Dr. Mohit, Dr. Sanjay, Ms. Atikasha

My family deserves endless gratitude for their unconditional, unequivocal, and loving support. My forever interested, encouraging and always enthusiastic my mother Mrs. Radha Devi, my father Mr. P.L Kotiyal, my elder brother Mr. Kuldeep Kotiyal, my sister in laws Mrs. Vijaya Kotiyal, my younger sister Mrs. Santoshi Pokhriyal, my brother in law Mr. Anup Pokhriyal they were always keen to know what I was doing and how I was proceeding. I extend my heartfelt thanks to my better half, Mrs. Sonam Kotiyal, whose unwavering support has been a constant source of strength. Her presence by my side has kept me balanced throughout the entirety of my research journey.

I express my sincere thanks to the funding organizations without whose support this work would not have been possible: Indian Council of Medical Research (ICMR), Ministry of Human Resource Development (MHRD),

Science & Engineering Research Board (SERB) and Indian Institute of Technology (B.H.U.). Varanasi.

In humble gratitude, I extend my deepest thanks to Lord Shri Kedar Baba, Badri Bishal, Maa Kali, and Kal Bhairava. It is with reverence that I acknowledge their divine presence and express my appreciation for the extraordinary opportunity bestowed upon me. Their blessings have not only granted me the chance to undertake this meaningful work but have also infused my mind with the strength needed to fulfill the assigned tasks.

Date: 13.02.2024

Place: Varanasi



(Akhilesh)

TABLE OF CONTENTS

Certificate	iii
Declaration by the Candidate	iv
Copyright Transfer Certificate	v
Acknowledgements	vi-ix
Contents	x-xvii
List of Figures	xviii-xxi
List of Tables	xxii
List of Symbols and Abbreviations	xxiv-xxv
Preface	xxvi-xxix
Chapter 1: Introduction and Literature Review	1-53
1.1 Introduction	1
1.2 Understanding the mechanisms underlying chemotherapy-induced neuropathic pain	3
1.2.1 Vincristine-induced peripheral neuropathy	3
1.2.2 Cisplatin-induced neuropathic pain	5
1.2.3 Peripheral sensitization	7
1.2.4 Central sensitization	9
1.2.5 Neuronal Damage and Axonal Dysfunction	10
1.2.6 Oxidative Stress, Mitochondrial Dysregulation and Inflammation	11
1.2.6 Increase ion channel activity	12
1.3 Pharmacotherapeutics for the treatment of CINP and their limitations	15
1.3.1 Tricyclic antidepressants (TCAs)	16
1.3.2 Serotonin–noradrenaline reuptake inhibitors (SNRIs)	16
1.3.3 Anticonvulsants	17
1.3.4 Opioids and NSAIDs	18
1.3.5 Anti-inflammatory compounds	18
1.4 Perspectives from preclinical data	20
1.4.1 TRP channel inhibition	20
1.4.2 TRPA1 and TRPV4 modulation	21
1.4.3 Antioxidants and neuroprotective agents	22
1.4.4 NMDA antagonists	23

1.5 Other pharmacological treatment	24
1.6 TRP channels as a potential drug target for CINP	25
1.6.1 Growing significance of TRPV1 channels in CINP	26
1.6.2 Crucial role of TRPA1 channels as regulators in CINP	28
1.6.3 Unveiling the significance of TRPM8 channel in CINP	29
1.6.4 TRP channels and cytokines/chemokines interplay in CINP	30
1.7 NMDA receptors system: A key player in the pathophysiology of CINP	33
1.7.1 NMDA mediated central sensitization across the ascending and descending pain pathways	33
1.7.2 NR2B assembly subunit of NMDA critically mediates CINP	38
1.8 Animal models for CINP	40
1.9 Drug failures stemming from preclinical model incompatibility	41
1.10 Bergenin: A potential therapeutic breakthrough for treatment of chronic pain	43
1.11 siRNA as a promising approach for the treatment of CINP	44
1.11.1 siRNA structure and function: a brief overview	44
1.12 Collecting evidence supporting TRPA1 channels as a potential therapeutic target for CINP	46
1.13 Current status of siRNA interventions as a near-future therapeutic tool	48
1.14 Current challenges and future prospects: a roadmap for advancement of siRNA therapeutics	50
1.15 Nano-carriers as promising candidates for siRNA delivery	51
Chapter 2: Rationale, Objectives and Plan of Work	54-63
2.1 Rationale	54
2.2 Objectives	56
2.3 Plan of work	58
2.3.1 Study I	58
2.3.2 Study II	59
2.3.3 Study III	62

Chapter 3: Materials & Methods	64-93
3.1 Drugs, chemicals and antibodies	64
3.2 Equipment and software	66
3.3 <i>In-vivo</i> studies	69
3.3.1 Experimental animals	69
3.3.2 Ethical committee approval	69
3.3.3 Animal model of chemotherapy induced neuropathic pain	69
3.3.3.1 Paclitaxel Model of Chemotherapy-Induced Neuropathic Pain	69
3.3.3.2 Combination chemotherapy model of chemotherapy-induced neuropathic pain	70
3.3.4 Experimental design	70
3.3.5 Intrathecal siRNA knockdown of TRPA1 expression	72
3.3.6 Preparation of liposomal formulation	73
3.3.6.1 Preparation of blank and TRPA1 siRNA based liposomal formulation	73
3.3.7 Characterization of blank and TRPA1 siRNA based liposomal formulation	74
3.3.7.1 Determination of particle size, polydispersity index and zeta potential	74
3.3.7.2 Morphological characterization	74
3.3.7.3 Infra-red (IR) spectroscopy	75
3.3.7.4 X-ray photoelectron spectroscopy (XPS) analysis	75
3.3.7.5 Thermogravimetric analysis	76
3.3.7.6 Differential scanning calorimeter analysis	76
3.3.8 Animal pain behavior tests	76
3.3.8.1 Tail flick test: Analgesic assay	76
3.3.8.2 Tail clip test	77
3.3.8.3 Pinprick test	77
3.3.8.4 Hargreaves test: Thermal hyperalgesia	77
3.3.8.5 von-Frey hair Test: Static allodynia	78

3.3.8.6	Paint brush test: Dynamic mechanical test	79
3.3.8.7	Cold plate test: Cold hyperalgesia test	79
3.3.8.8	Acetone evaporation test	80
3.3.8.9	Conditioned place preference: Spontaneous ongoing pain assay	80
3.3.9	Behavioral neurotoxicity assays	81
3.3.9.1	Rota-rod test	81
3.3.9.2	Open field test	82
3.3.10	Tissue harvesting and storage	82
3.3.11	Biochemical assays	82
3.3.11.1	Lipid peroxidation	82
3.3.11.2	Nitrite estimation	83
3.3.11.3	Glutathione estimation	83
3.3.11.4	Quantification of superoxide dismutase (SOD)	84
3.3.12	Evans blue assay	84
3.3.13	Molecular biology studies	85
3.3.13.1	Western blot analysis	85
3.3.13.2	Reverse transcription polymerase chain reaction (RT PCR) analysis	87
3.4	<i>In-silico</i> study	89
3.4.1	Homology modeling	89
3.4.1.1	NCBI Database and Sequence Retrieval	89
3.4.1.2	Sequence Alignment	90
3.4.1.3	Structure prediction and homology modelling of TRPA1 and TRPM8	90
3.4.1.4	Structure-based virtual screening	91
3.4.1.5	Molecular dynamics simulation NCBI Database and Sequence Retrieval	92
3.5	Statistical analysis	93
Chapter 4:	Development and Pharmacological Validation of Clinically Mimicable Animal Model of Combined Chemotherapy-Induced Neuropathic Pain	94-135
4.1	Introduction	94

4.2 Experimental procedure	96
4.3 Results and discussion	98
4.3.1 Effect of combined chemotherapy on daily body weight changes in rats	98
4.3.2 Combination chemotherapy causes pain like behaviours in rats	100
4.3.2.1 Combination chemotherapy causes thermal and mechanical hypersensitivity in rats	100
4.3.2.2 Combined chemotherapy develops cold hypersensitivity in rats	103
4.3.3 Modulation of TRP channels, NR2B, neuropeptides and inflammatory signaling in DRG and Spinal cord of neuropathic rats	105
4.3.3.1 Combined chemotherapy upregulates TRP Channels mRNA expression in DRG and spinal cord of rats	105
4.3.3.2 Combined chemotherapy significantly upregulated NR2B mRNA expression in DRG and spinal tissue	107
4.3.3.3 Combined chemotherapy increases neuropeptides levels in the DRG and spinal cord of rats	109
4.3.3.4 Combined chemotherapy-induced neuro-inflammation in DRG and spinal cord of rats	111
4.3.4 Biochemical observations and interpretation	112
4.3.4.1 Combined chemotherapy suppressed the antioxidant enzyme activity in sciatic nerve of rats	112
4.3.4.2 Combined chemotherapy increases MDA and Nitrite levels in sciatic nerve of rats	114
4.3.5 Pharmacological validation of novel combined chemotherapy model of CINP	116
4.3.5.1 Gabapentin does not affect body weight in chemotherapy treated rats	116
4.3.5.2 Gabapentin alleviates chemotherapy-induced mechanical and thermal pain behaviour in rats	117

4.3.5.3	Gabapentin alleviates chemotherapy-induced cold pain behaviour in rats	120
4.3.5.4	Gabapentin suppressed mRNA expression of TRPV1, TRPA1 and TRPM8 in DRG and spinal cord tissue of neuropathic rats	122
4.3.5.5	Gabapentin treatment decreases NR2B mediated Iba1 expressions in DRG and spinal cord of neuropathic rats	124
4.3.5.6	Gabapentin treatment decreases ICAM-1 expression in DRG and spinal cord of neuropathic rats	126
4.3.5.7	Gabapentin treatment suppressed CGRP and Substance P in CINP rats	127
4.3.5.8	Gabapentin treatment suppressed neuro-inflammatory cascade in neuropathic rats	130
4.3.5.9	Gabapentin treatment alleviated oxidative stress and increased antioxidant enzyme activity in sciatic nerve of neuropathic rats	132
4.3.6	Overall Summary and key findings	134
4.4	Outcomes	135
Chapter 5:	Modulation of TRPA1/TRPV1/NR2B signaling by Bergenin in a Rat Model of Chemotherapy-Induced Neuropathic Pain	136-180
5.1	Introduction	136
5.2	Experimental Design	138
5.3	Results and discussion	139
5.3.1	Assessment of general toxicity	139
5.3.2	Bergenin ameliorates chemotherapy-induced mechanical allodynia (static and dynamic) in rats	140
5.3.3	Bergenin alleviates chemotherapy-induced thermal hyperalgesia in rats	142
5.3.4	Bergenin attenuates mechanical hyperalgesia in rats administered with combination chemotherapy	143

5.3.5	Bergenin treatment decreased chemotherapy-induced cold pain behavior in rats	144
5.3.6	Bergenin did not altered the pain threshold of healthy naïve rats	147
5.3.7	Bergenin attenuates spontaneous ongoing pain in neuropathic rats without causing drug addiction	148
5.3.8	Bergenin treatment does not cause locomotor impairment and motor in-coordination in rats	153
5.3.9	Bergenin modulates mRNA and protein expressions of TRP channels in DRG and spinal cord of neuropathic rats	155
5.4	Bergenin decreased NR2B mediated ICAM-1 and Iba1 expression in DRG and spinal cord of neuropathic rats	158
5.5	Bergenin restored blood-spinal cord barrier integrity in chemotherapy-administered rats	161
5.6	Bergenin attenuates oxido-inflammatory cascade in DRG and spinal cord of neuropathic rats	164
5.7	<i>In-silico</i> studies	167
5.7.1	Homology modelling	167
5.7.2	Molecular Docking	169
5.7.3	Molecular Dynamics Simulation	171
5.7.4	Overall Summary	178
5.7.4	Outcomes	180
Chapter 6:	Development of TRPA1 siRNA Based Nanoforumulation for the Treatment of Chemotherapy-Induced Neuropathic Pain	181-211
6.1	Introduction	181
6.2	Experimental design	183
6.3	Results and discussion	184
6.3.1	Validation of TRPA1-siRNA knockdown efficacy in rats	184
6.3.2	Physicochemical Characterization of blank liposome and TRPA1 siRNA loaded liposome	187
6.3.3	Scanning electron microscopy (SEM) Analysis	189

6.3.4 Atomic Force Microscopy (AFM) analysis	191
6.3.5 Fourier-transform infrared analysis of liposome	192
6.3.6 Differential Scanning Calorimetry (DSC) analysis	194
6.3.7 Thermogravimetric Analysis (TGA) of liposome formulation	195
6.3.8 X-ray photoelectron spectroscopy (XPS) analysis	196
6.4 Agarose gel electrophoresis for entrapment efficiency of TRPA1 siRNA liposome	198
6.5 TRPA1 siRNA based liposomal formulation attenuates chemotherapy-induced mechanical and cold allodynia in rats	200
6.6 TRPA1 siRNA based liposomal formulation downregulates TRPA1 and Iba1 protein expressions in spinal cord of neuropathic rats	203
6.7 Liposomal formulation downregulates TRPA1 mediated ICAM-1 protein expressions in spinal cord of neuropathic rats	204
6.8 Liposomal formulation downregulates TRPA1 and IL-6 mRNA expressions in DRG of neuropathic rats	206
6.9 TRPA1 siRNA formulations does not affect locomotor activity and motor coordination of rats	208
Chapter 7: Summary & Conclusions	212-219
7.1 Summary	212
7.2 Conclusion	217
7.3 Limitations and outlook for future work	218
References	220-242
List of Publications and Conferences Attended	243-248
Brief Bio-Sketch	249-250

LIST OF FIGURE

		Page No.
Chapter 1	Introduction and Literature review	
Fig.1.1	Pathophysiological events contributing to CINP	3
Fig.1.2	Illustrates the mechanisms of chemotherapy-induced peripheral neuropathic pain	6
Fig.1.3	Peripheral sensitization under CINP	8
Fig.1.4	Molecular mechanism of central sensitization in CINP	10
Fig.1.5	Illustrative representation of the mechanism of chemotherapy-induced peripheral neuropathy (CIPN)	14
Fig.1.6	A Mechanistic understanding of the TRP channels to induce CINP	32
Fig.1.7	Role of NMDA receptor system in the neurobiology of CINP	35
Fig.1.8	Chemical structure of Bergenin	44
Fig.1.9	Silencing of the siRNA-regulated gene in eukaryotes	46
Fig.1.10	TRPA1 as promising target in chemotherapy-induced neuropathic pain	48
Chapter 3	Materials & Methods	
Fig.3.1	Experimental Timeline	72
Chapter 4	Development and Pharmacological Validation of Clinically Mimicable Animal Model of Combined Chemotherapy-Induced Neuropathic Pain	
Fig.4.1	Effect of combination chemotherapy on body weight of rats	99
Fig.4.2	Combination chemotherapy induces persistent pain behavior in rats	102
Fig.4.3	Combination chemotherapy induces cold hypersensitivity in rats	104
Fig.4.4	Combined chemotherapy increases TRP (TRPA1, TRPV1 and TRPM8) mRNA expression in dorsal root ganglion (DRG) and spinal cord of rats	106
Fig.4.5	Combined chemotherapy increases NR2B mRNA expression in dorsal root ganglion (DRG) and spinal cord of rats	108
Fig.4.6	Combined chemotherapy upregulates neuropeptides levels in rats	110
Fig.4.7	Combined chemotherapy-induced neuro-inflammatory markers in rats	112

Fig.4.8	Combined chemotherapy causes biochemical changes in rats	115
Fig.4.9	Effect of gabapentin on daily body weight changes in neuropathic rats	117
Fig.4.10	Effect of gabapentin on thermal and mechanical pain behavior in neuropathic rats	119
Fig.4.11	Effect of gabapentin on cold hypersensitivity of neuropathic rats	121
Fig.4.12	Effect of gabapentin on chemotherapy induced-TRP (TRPA1, TRPV1, TRPM8) channel mRNA expression in dorsal root ganglion (DRG) and spinal cord of rats	123
Fig.4.13	Effect of gabapentin on protein expressions of NR2B and Iba1 in dorsal root ganglion and spinal cord of neuropathic rats	125
Fig.4.14	Effect of gabapentin on protein expressions of ICAM-1 in dorsal root ganglion and spinal cord of CINP rats	127
Fig.4.15	Effect of gabapentin on chemotherapy-induced upregulated neuropeptides in rats	129
Fig.4.16	Effect of gabapentin on chemotherapy-induced neuro-inflammatory markers in rats	131
Fig.4.17	Effect of gabapentin on chemotherapy-induced biochemical changes in rats.	133
Fig.4.18	Working hypothesis and overall summary of the results	134
Chapter 5	Modulation of TRPA1/TRPV1/NR2B signaling by Bergenin in a Rat Model of Chemotherapy-induced Neuropathic Pain	
Fig.5.1	Effect of Bergenin on static and dynamic mechanical allodynia in neuropathic rats	141
Fig.5.2	Effect of Bergenin on thermal hypersensitivity in rats	142
Fig.5.3	Effect of Bergenin on mechanical hyperalgesia in neuropathic rats	144
Fig.5.4	Effect of Bergenin on CINP-induced cold hypersensitivity in rats	146
Fig.5.5	Effect of bergenin on basal pain response in healthy naïve rats	148
Fig.5.6	Effect of Bergenin on spontaneous ongoing pain in chemotherapy-treated rats. (A, B and C) Conditioned place preference (CPP) for Bergenin	150
Fig.5.7	Effect of gabapentin on spontaneous ongoing pain in chemotherapy-treated rats. (A, B and C) Conditioned place preference (CPP) for Gabapentin	151

Fig.5.8	Effect of Morphine on spontaneous ongoing pain in chemotherapy-treated rats. (A, B and C) Conditioned place preference (CPP) for Morphine	152
Fig.5.9	Effect of Bergenin on locomotor and motor coordination activity of rats (A, B and C)	154
Fig. 5.10	Effect of Bergenin on CINP-induced increase in TRP channel mRNA expressions in L4-L5 dorsal root ganglion (DRG) and spinal cord of rats	156
Fig.5.11	Effect of Bergenin on CINP-induced increase in NR2B and TRPA1 protein expressions in dorsal root ganglion and spinal cord of rats	157
Fig.5.12	Effect of Bergenin on chemotherapy-induced protein expressions of TRPV1, ICAM-1 and IBA1 in dorsal root ganglion and spinal cord of rats	160
Fig.5.13	Effect of Bergenin on CINP-induced disruption in blood spinal cord integrity of rats	163
Fig.5.14	Effect of Bergenin on blood-spinal tight junction proteins and neuro-inflammation in L4-L5 spinal cord of neuropathic rats	165
Fig.5.15	Effect of Bergenin on oxidative stress induced by combination chemotherapy in rats	166
Fig.5.16	<i>In-silico</i> studies of Bergenin with TRP channels	168
Fig.5.17	Illustration of 2D ligand interlinkage and 3D binding posture of Bergenin and TRPV1 protein	170
Fig.5.18	Ramachandran plots for TRPM8 protein structure.	170
Fig.5.19	MD trajectory data of Bergenin with TRPA1 interaction	172
Fig.5.20	MD trajectory data of Bergenin and TRPV81 interaction	174
Fig.5.21	MD trajectory data of Bergenin and TRPV81 interaction	176
Fig.5.22	Working hypothesis and overall summary of the results	179
Chapter 6	Development of TRPA1 siRNA Based Nanoformulation for the Treatment of Chemotherapy-Induced Neuropathic Pain	
Fig.6.1	Effect of siRNA in TRPA1 mRNA expression in rats	186
Fig.6.2	Effect of siRNA in TRPA1 protein expression in rats	186
Fig.6.3	High resolution transmission electron microscopy	189
Fig.6.4	Representative images of liposome formulations	190

Fig.6.5	Representative images of blank and TRPA1 siRNA liposome formulations	190
Fig.6.6	Atomic force microscopy (AFM) images of TRPA1 siRNA-loaded liposomal formulation	192
Fig.6.7	FTIR spectra of TRPA1 siRNA-loaded liposomal formulation	193
Fig.6.8	Differential scanning calorimetry curves of TRPA1 siRNA-loaded liposomal formulation	195
Fig.6.9	Thermogravimetric analysis (TGA) of blank and siRNA loaded liposome	196
Fig.6.10	X-ray photoelectron spectroscopy (XPS) survey spectrum of siRNA-loaded liposomal formulation	198
Fig.6.11	Agarose gel electrophoresis analysis of TRPA1 siRNA loading in liposomal	200
Fig.6.12	Effect of liposomal TRPA1 siRNA formulation on alleviating chemotherapy-induced mechanical allodynia in rats	202
Fig.6.13	Effect of liposomal TRPA1 siRNA formulation on alleviating chemotherapy-induced cold allodynia in rats	202
Fig.6.14	Effect of liposomal TRPA1 siRNA formulation on TRPA1 and Iba1 protein expressions in neuropathic rats	204
Fig.6.15	Effect of liposomal TRPA1 siRNA formulation on ICAM-1 and TNF- α protein expressions in neuropathic rats	206
Fig.6.16	Effect of liposomal TRPA1 siRNA formulation on TRPA1 and IL6 mRNA expressions in neuropathic rats	208
Fig.6.17	Effect of the TRPA1 siRNA-based nano-formulation on the locomotor activity and motor coordination of rats with CINP	210

LIST OF TABLE

		Page No.
Chapter 1	Introduction and Literature review	
Table 1	Currently available drugs for the treatment of CINP and their limitations	24
Chapter 2	Rationale, Objectives and Plan of work	
Table 2.1	Animal grouping for time course study of animal model	59
Table 2.2	Animal grouping for pharmacological validation of animal model	59
Table 2.3	Animal grouping to investigate the effect of Bergenin on chemotherapy-induced neuropathic pain in rats	60
Table 2.4	Animal grouping to study the effect of Bergenin on blood-spinal cord barrier integrity in animal model of CINP in rats	61
Table 2.5	Animal grouping to study the effect of Bergenin on basal pain response in rats	61
Table 2.6	Animal grouping for the validation of TRPA1-siRNA knockdown efficacy in rats	62
Table 2.7	Animal grouping to study the efficacy and safety of TRPA1-siRNA liposomal formulation in neuropathic rats	63
Chapter 3	Materials and Methods	
Table 3.1	List of drugs, chemicals and antibodies	64
Table 3.2	List of equipment & software	67
Table 3.3	Composition of RIPA buffer	86
Table 3.4	Loading buffer recipe	86
Table 3.5	Running buffer recipe	87
Table 3.6	Primers used in RT PCR analysis	88
Chapter 6	Development of TRPA1 siRNA Based Nanoforumulation for the Treatment of Chemotherapy-induced Neuropathic Pain	
Table 6.1	Particle size, zeta potential and poly dispersity of blank and siRNA loaded liposomes	188

LIST OF SYMBOLS AND ABBREVIATIONS

AMPA	α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
ANOVA	Analysis of variance
ATP	Adenosine tri-phosphate
BDNF	Brain-derived neurotrophic factor
Ber	Bergenin
BLAST	Basic Local Alignment Search Tool
BSA	Bovine serum albumin
CaMKII	Calcium/calmodulin-dependent protein kinase II
Camp	Cyclic adenosine monophosphate
CC	Combination chemotherapy
CDK	Cyclin-dependent kinase
CGRP	Calcitonin gene-related peptide
CINP	Chemotherapy-induced neuropathic pain
CNS	Central nervous system
COX	Cyclooxygenase
CPCSEA	Committee for the Purpose of Control and Supervision of Experiments on Animals
CPP	Conditioned place preference
CREB	Camp response element-binding protein
DMSO	Dimethyl sulfoxide
DRG	Dorsal root ganglion
DRG	Dorsal root ganglion
DTNB	5,5'-dithiobis (2-nitrobenzoic acid)
DTNB	5,5'-dithiobis (2-nitrobenzoic acid)
ECL	Enhanced chemiluminescence
EDTA	Ethylenediaminetetraacetic acid
EGTA	Ethylene glycol-bis(β -aminoethyl ether)-N,N,N',N'-tetraacetic acid
ERK	Extracellular signal-related kinase
GABA	Gamma-aminobutyric acid
GP	Gabapentin
GPCR	G protein coupled receptors
GSH	Reduced glutathione
IASP	International Association for the Study of Pain
IBA1	Ionized calcium binding adaptor molecule 1
ICD	International Classification of Disease

IL-1 β	Interleukin-1 Beta
IL-1 β	Interleukin-1 Beta
LPO	Lipid peroxidation
LTP	Long-term potentiation
MAPK	Mitogen activated protein kinase
MD	Molecular dynamic
MDA	Malondialdehyde
NCBI	National Centre for Biotechnology Information
NF- $\kappa\beta$	Nuclear factor kappa β
NMDA	N-methyl-D-aspartate
NPT	Normal pressure and temperature
NR2B	N-methyl D-aspartate receptor subtype 2B
NS	Non-significant
OSM-3	Osmotic avoidance abnormal protein 3
OXL	Oxaliplatin
PDB	Protein data bank
PME	Particle Mesh Ewald
PTX	Paclitaxel
RC	Ramachandran
REPSA	Reversible reference system propagator algorithms
RMSD	Root mean square deviation
RMSF	Root mean square fluctuation
ROS	Reactive oxygen species
SOD	Superoxide dismutase
TBARS	Thiobarbituric acid reactive substances
TNF- α	Tumour necrosis factor-alpha
TRPA1	Transient receptor potential ankyrin 1
TRPM8	Transient receptor potential melastatin 8
TRPV1	Transient receptor potential vanilloid 1
VCAM	Vascular cell adhesion molecule
VCR	Vincristine

PREFACE

Cancer is the second leading cause of death in the world and one of the biggest threats to global public health, with reportedly 23.6 million incident cancer cases and 10.5 million cancer deaths across 204 countries and territories in 2021 (Brianna and Lee, 2023). Chemotherapy, a cornerstone in cancer treatment, has shown efficacy, but its use is accompanied by the with severe side effect of chemotherapy-induced neuropathic pain (CINP). CINP persist almost 30–90% of patients undergoing neurotoxic chemotherapy, manifesting as sensory, motor, and autonomic disorders, with significant impact on patients' quality of life. Despite several efforts made by pain scientists in preclinical studies, nearly 98% of drugs fail in clinical trials due to various factors. One major contributor to these failures is the lack of an optimal clinically representative animal model that accurately recapitulates the actual conditions associated with CINP. Therefore, there is an urgent need for novel and further development of effective therapeutic strategies for establishment of a robust animal model that accurately recapitulates the clinical condition of CINP. Based on the drug prescription record for cancer survival as well as recent literature on clinical studies, it is suggested that chemotherapeutic agents are generally prescribed in a combination of two or three drugs. Numerous studies documented that the combined chemotherapy regimen of vincristine, cisplatin and paclitaxel is the most prescribed treatment for cancers like ovarian, breast and hematological malignancies. In this context, we propose a three-step strategy to develop and validate a combination-based rat model of CINP, incorporating face validity, predictive validity, and constructive validity. Our study delves into the cellular and molecular pathways underlying CINP, with a particular focus on transient receptor potential (TRP) channels, such as TRPA1, TRPV1, and TRPM8. These channels play pivotal roles in thermal, mechanical, and cold hypersensitivity during CINP. Treatment with paclitaxel, bortezomib and cisplatin led to an increase in expression of both TRPA1/TRPV1 mediated mitogen-activated protein kinases (MAPK) pathways followed by the release of pro-inflammatory cytokines and chemokines resulting in neurogenic inflammation. Additionally, we explored the interaction between N-methyl-D-aspartate receptors (NMDARs) and TRP channels, presenting a novel approach to target NMDAR function indirectly.

Recognizing the limitations of current CINP treatments, including adverse effects and drug interactions, we shift our focus to natural phytochemicals. Bergenin, a promising compound, was investigated for its therapeutic potential against CINP. We have dissected the detailed mechanism of action of Bergenin involving modulation of TRP channels-mediated NR2B signalling in DRG and spinal cord of neuropathic rats. Virtual screening and dynamics studies were conducted to evaluate Bergenin's binding interactions and thermodynamic stability with TRPA1, TRPV1, and TRPM8.

The therapeutic potential of targeting TRPA1 in managing chemotherapy-induced peripheral neuropathy (CIPN) is widely acknowledged. However, numerous reports highlight the significant drawbacks of TRPA1 antagonists, including severe side effects such as respiratory depression, cardiovascular abnormalities, and hypersensitivity reactions. Given the debilitating nature of CIPN, it becomes imperative to explore alternative and more specific treatment approaches tailored to address these challenges. Our study introduces a ground-breaking approach to target TRPA1 nociceptors using small interfering RNA (siRNA) delivered intrathecally. Overcoming challenges in siRNA delivery into the systemic circulation, including rapid degradation, excretion, and blood-brain barrier permeability, we present a lipid-based nano-carrier delivery system. This innovative system, developed with state-of-the-art facilities, demonstrates biocompatibility, biodegradability, low toxicity, and efficient entrapment efficacy, paving the way for a potential breakthrough in CINP management through intravenous administration. In summary, our comprehensive study aims to address the scientific and clinical gaps in CINP research, offering a multifaceted approach from animal model development to novel therapeutic interventions. The potential implications of our findings extend beyond CINP, influencing the broader landscape of cancer treatment and chronic pain management. The present thesis is divided into seven chapters and a brief description is given below:

Chapter 1 is the opening chapter extensively reviews existing literature on chemotherapy-induced neuropathic pain (CINP), portraying it as a profound disorder. It delves into the motivation behind the research, providing insights into the study's background. The section elucidates definitions, terminologies, mechanisms, and constraints associated with current therapeutic approaches for CINP. A thorough

exploration of the intricate interplay of TRP channels in diverse signaling pathways integral to the neurobiology of CINP is presented. The chapter emphasizes the need for innovative animal models to better simulate the disorder's complexity, aiming to improve translational relevance and enhance the efficacy of therapeutic interventions.

Chapter 2 outlines the rationale and objectives of the research, introducing the study's hypothesis and detailing the experimental design. It articulates multiple objectives framed through a multidisciplinary, state-of-the-art approach, incorporating *in-silico* and *in-vivo* tools. The chapter serves as a concise yet thorough roadmap, highlighting the thoughtful planning and integration of diverse methodologies.

Chapter 3 providing a comprehensive account of the material and methods employed, this section offers a detailed overview of various experimental techniques, elucidating their working principles and any modifications made. The discussion encompasses *in-silico* techniques, sample size determination, CINP models, surgical procedures, tissue harvesting methods, sample processing procedures, reagent preparation and composition, as well as biochemical assays and molecular biology techniques.

Chapter 4 presents the experimental work and findings of the first study conducted to evaluate various aspects of the hypothesis. It details the development and validation of a clinically relevant, combination-based chemotherapeutic model of peripheral neuropathy using behavioral, pharmacological, and molecular tools. The three-step strategy employed demonstrates face, predictive, and constructive validities.

Chapter 5 another part of the experimental work focuses on studying the effect of Bergenin as a potential phytochemical in an animal model of chemotherapy-induced neuropathic pain. The detailed mechanism of action of Bergenin, involving modulation of TRP channels-mediated NR2B activation in DRG and spinal cord of neuropathic rats, is dissected. *In-silico* studies were performed to validate Bergenin's binding affinity with different TRP channels.

Chapter 6 summaries the development of TRPA1 siRNA-based nano-formulation for the treatment of CINP. The study evaluates the efficacy of TPRA1-siRNA liposomal formulation in animal model of CINP via intrathecal/intravenous

administration. Addressing challenges associated with siRNA delivery, a lipid-based nano-carrier delivery system is successfully engineered, demonstrating significant attributes including biocompatibility, biodegradability, low toxicity, and high entrapment efficacy.

Chapter 7 summaries and the key findings of the experimental work of the thesis and includes the discussion on the results observed in the present work and describes the advantages of new animal model over conventional monotherapy based model of CINP. It delves into detailed insights gained from the experimental work on the novel mechanisms of Bergenin and TRPA1 siRNA in their anti-nociceptive action against CINP. The chapter concludes by summarizing the overall thesis work and providing insights into the future scope of the research. Potential avenues for further investigation and application of the novel treatment strategies are outlined, emphasizing the ongoing commitment to treat CINP.